Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
复制标题
免疫治疗对晚期或转移性食管鳞状细胞癌患者的疗效和安全性比较：系统评价和网络荟萃分析
DOI：
10.1186/s12885-022-10086-5
复制
发表时间：
2022-09-17
期刊：
影响因子：
3.8
通讯作者：
Zhao, Lei
中科院分区：
文献类型：
--
作者：
Gao, Tian-Tian;Shan, Jia-Hui;Yang, Yu-Xian;Zhang, Ze-Wei;Liu, Shi-Liang;Xi, Mian;Liu, Meng-Zhong;Zhao, Lei
该研究旨在比较各种免疫检查点抑制剂对晚期或转移性食管鳞状细胞癌（ESCC）患者的疗效和安全性。从2000年1月1日至2021年12月19日，我们检索了Medline、Web of Science、Cochrane Central Register of Controlled Trials、Embase、Clinical Trials.gov和几个国际会议数据库。我们通过贝叶斯网络meta分析来评估不同治疗之间的相对效果。结果包括总生存期（OS）、无进展生存期（PFS）、总缓解率和不良事件。纳入了10项符合条件的试验，共5250例患者。在一线环境中，托利帕单抗和Camrelizumab联合化疗分别在OS（概率为61%）和PFS（概率为37%）上排名第一。在难治性患者中，辛替单抗和Camrlizumab最有可能在OS（概率为37%）和PFS（概率为94%）上排名第一。在临床试验中，与免疫治疗相关的毒性是可控的。Camrelizumab和Nivolumab分别在首次和难治性环境中具有较少的3级或更高级别不良事件。本研究发现，对于晚期或转移性ESCC患者，在一线环境中，托利帕单抗和Camrelizumab加化疗可能分别是OS和PFS的最佳选择。辛替单抗和Camrelizumab分别是难治性OS和PFS患者的首选方案。免疫治疗的毒性与常规化疗不同，但在ESCC患者中是可控的。普洛斯彼罗注册号：（CRD 42021261554）。在线版本包含补充材料，下载地址：10.1186/s12885-022-10086-5。
The study aimed to compare efficacy and safety of various immune checkpoint inhibitors for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). We searched Medline, Web of Science, Cochrane Central Register of Controlled Trials, Embase, Clinical Trials.gov and several international conference databases from January 1, 2000 to December 19, 2021. We conducted Bayesian network meta-analysis to assess the relative effects among treatments. Outcomes included overall survival (OS), progression-free survival (PFS), overall response rate and adverse events. Ten eligible trials with 5250 patients were included. Toripalimab and Camrelizumab plus chemotherapy were preferred to rank first on OS (probability, 61%) and PFS (probability, 37%) in the first-line setting, respectively. In refractory patients, Sintilimab and Camrlizumab were most likely to be ranked first on OS (probability, 37%) and PFS (probability, 94%). The toxicity related to immunotherapy was manageable in clinical trials. Camrelizumab and Nivolumab had the less adverse events of grade 3 or higher in the first and refractory setting, respectively. This study found that Toripalimab and Camrelizumab plus chemotherapy were likely to be the best option in terms of OS and PFS in the first-line setting for patients with advanced or metastatic ESCC respectively. Sintilimab and Camrelizumab were the preferred options for OS and PFS in refractory patients respectively. The toxicity of immunotherapy was different from conventional chemotherapy, but manageable in patients with ESCC. PROSPERO registration number: (CRD 42021261554). The online version contains supplementary material available at 10.1186/s12885-022-10086-5.
登录
查看更多内容
影响因子：
39.2
作者：
Hutton, Brian;Salanti, Georgia;Moher, David
通讯作者：
Moher, David
影响因子：
8.8
作者：
Petrasch, S;Welt, A;Reinacher, A;Graeven, U;Konig, M;Schmiegel, W
通讯作者：
Schmiegel, W
影响因子：
51.1
作者：
Kato, Ken;Cho, Byoung Chul;Kitagawa, Yuko
通讯作者：
Kitagawa, Yuko
影响因子：
51.1
作者：
Huang, Jing;Xu, Jianming;Zou, Jianjun
通讯作者：
Zou, Jianjun
影响因子：
3.8
作者：
Shim, Sung Ryul;Kim, Seong-Jang;Ruecker, Gerta
通讯作者：
Ruecker, Gerta